Peregrine Pharmaceuticals on the Hot List

Los Angelas, CA -- (SBWIRE) -- 01/07/2013 -- Peregrine Pharmaceuticals (NASDAQ:PPHM) put out a press release and provided an update from its internal review of discrepancies from its Phase II randomized, double-blind placebo-controlled trial of bavituximab in second-line non-small cell lung cancer (NSCLC) in 121 patients.

A little over two months ago, on September 24th, the stock price plummeted as the company announced that there were major discrepancies in the study on the bavituximab drug which it only recently announced the results for. Investors saw shares fall $4.23 (78.48%) and closed at $1.16/share on volume of 68.4 million shares. For weeks after the stock feel even further to a low of $0.65. Analysts came out and adjusted their price targets to significantly lower prices.

Today the review diminishes the news from the previous damaging report. The recent review was prompted by the discovery of vial coding discrepancies while preparing for an end of Phase II meeting with the FDA. The internal review included a thorough operational review of multiple third-party vendor operations at sites worldwide, testing of investigational product used in the trial, additional patient sample testing to determine drug levels and a review of immunogenicity testing results from the trial. The results of the extensive internal review indicate that discrepancies are isolated to the placebo and 1 mg/kg treatment arms of the trial and that there was no evidence of discrepancies in the 3 mg/kg treatment arm of the trial.

Can PPHM Move Up Further? If Yes, How far It can Go? Find Out Here

DISCLAIMER:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com